Clinical Trial 46851

Garden Grove, CA 92845


This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5).

  • Male or female, 18 to 60 years of age, inclusive.
  • Current diagnosis of schizophrenia according to DSM-5 criteria as determined by the modified Structured Clinical Interview for DSM-5 (modified SCID-5).
  • Diagnosis of schizophrenia for a minimum of 1 year before Visit 1.
  • Current psychotic episode < 4 weeks duration at Visit 1.
  • PANSS total score ≥ 70 and ≤ 120 at Visit 1 and Visit 2.
  • Rating of at least 4 (moderate) on at least two of the following four PANSS positive symptoms: delusions (P1), hallucinatory behavior (P3), conceptual disorganization (P2), suspiciousness/persecution (P6) at Visit 1 and Visit 2.
  • Patient must identify a caregiver who provides consent to participate in the study.
  • In the opinion of the Investigator, the patient has significant risk for suicidal behavior during the course of his/her participation in the study.

Qualified Participants May Receive:

Monetary compensation for participation.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.